Cellular immunotherapy (CI), where have we been and where are we going?

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Previous reviews have detailed the development of cellular therapies using immunologically nonspecific lymphokine activated killer cells (LAK), activated killer monocytes (AKM), and eventually tumor specific tumor infiltrating lymphocytes (TIL). The innovations in large scale cell culture methodologies and the developments in immune assessment approaches have made the therapies more widespread as well as more effective against a variety of tumor histologies.

Original languageEnglish
Title of host publicationPrinciples of Cancer Biotherapy
Subtitle of host publication5th Edition
Number of pages22
StatePublished - 2009

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Cellular immunotherapy (CI), where have we been and where are we going?'. Together they form a unique fingerprint.

Cite this